XNAS
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.81 | -0.86 | -6.17% | $0 | ❌ Miss | -1.06% | -11.05% | — |
| 2026-03-17 | Q4 2025 | -0.69 | -0.88 | -27.54% | $8.7M | ❌ Miss | +2.09% | -13.47% | -11.92% |
| 2025-11-10 |
| Q3 2025 |
| -0.61 |
| -0.84 |
| -37.70% |
| $322,569 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | -0.60 | -0.70 | -16.67% | $1.8M | ❌ Miss | -0.43% | +2.74% | +1.42% |
| 2025-03-17 | Q4 2024 | -0.58 | -0.80 | -37.93% | $2.2M | ❌ Miss | +3.20% | +18.34% | +4.86% |
| 2024-08-09 | Q2 2024 | -0.38 | -0.27 | +28.95% | $3.3M | ✅ Beat | +7.54% | +61.88% | +41.67% |
| 2024-05-14 | Q1 2024 | -0.39 | -0.41 | -5.13% | $2.3M | ❌ Miss | +0.08% | -21.30% | -20.00% |
| 2024-04-01 | Q4 2023 | -0.62 | -1.55 | -150.00% | $2.5M | ❌ Miss | -2.38% | +2.16% | +6.48% |
Showing last 8 quarters.